ECSP21085693A - Moléculas de unión a tigit y pd-1/tigit - Google Patents

Moléculas de unión a tigit y pd-1/tigit

Info

Publication number
ECSP21085693A
ECSP21085693A ECSENADI202185693A ECDI202185693A ECSP21085693A EC SP21085693 A ECSP21085693 A EC SP21085693A EC SENADI202185693 A ECSENADI202185693 A EC SENADI202185693A EC DI202185693 A ECDI202185693 A EC DI202185693A EC SP21085693 A ECSP21085693 A EC SP21085693A
Authority
EC
Ecuador
Prior art keywords
tigit
binding molecules
chemotherapy
bind
human
Prior art date
Application number
ECSENADI202185693A
Other languages
English (en)
Inventor
Yiqing Feng
James David Pancook
Naresh Kumar
Yang Zhao
Stephanie Marie Truhlar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP21085693A publication Critical patent/ECSP21085693A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a las moléculas de polipéptidos que se unen a TIGIT humano, y a las moléculas de polipéptidos que se unen a PD-1 humano y a TIGIT humano, y son útiles para tratar tumores sólidos, solas y en combinación con quimioterapia y/o radiación ionizante.
ECSENADI202185693A 2019-05-29 2021-11-26 Moléculas de unión a tigit y pd-1/tigit ECSP21085693A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962853816P 2019-05-29 2019-05-29

Publications (1)

Publication Number Publication Date
ECSP21085693A true ECSP21085693A (es) 2021-12-30

Family

ID=71070067

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202185693A ECSP21085693A (es) 2019-05-29 2021-11-26 Moléculas de unión a tigit y pd-1/tigit

Country Status (22)

Country Link
US (1) US20220227860A1 (es)
EP (1) EP3976652A1 (es)
JP (2) JP7241207B2 (es)
KR (1) KR20220004120A (es)
AR (1) AR118980A1 (es)
AU (1) AU2020283817A1 (es)
BR (1) BR112021021795A2 (es)
CA (1) CA3139025A1 (es)
CL (1) CL2021003039A1 (es)
CO (1) CO2021015610A2 (es)
CR (1) CR20210573A (es)
DO (1) DOP2021000241A (es)
EA (1) EA202192796A1 (es)
EC (1) ECSP21085693A (es)
IL (1) IL287765A (es)
JO (1) JOP20210314A1 (es)
MA (1) MA56029A (es)
MX (1) MX2021014472A (es)
PE (1) PE20220505A1 (es)
SG (1) SG11202112725XA (es)
TW (1) TWI760751B (es)
WO (1) WO2020242919A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7194324B2 (ja) 2017-01-05 2022-12-22 カール メディカル リミテッド ＳＩＲＰα－４１ＢＢＬ融合タンパク質およびその使用方法
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
EP3565579B9 (en) 2017-01-05 2023-10-04 KAHR Medical Ltd. A pd1-41bbl fusion protein and methods of use thereof
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
US20240076346A1 (en) * 2021-01-13 2024-03-07 Kahr Medical Ltd. Type i membrane proteins heterodimers and methods of use thereof
TW202327610A (zh) * 2021-08-30 2023-07-16 美商G1治療公司 具有檢查點抑制劑抗性或抗性易感性之晚期性/轉移性癌症之改良治療
TW202337897A (zh) * 2021-11-18 2023-10-01 大陸商信達生物製藥（蘇州）有限公司 抗ｐｄ－１抗體和抗ｖｅｇｆ－ａ抗體的藥物組合及其使用方法
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3021869T3 (pl) * 2013-07-16 2020-11-16 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT
MX2016017288A (es) 2014-07-16 2017-06-27 Genentech Inc Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer.
JO3664B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme أجسام مضادة لـ tigit
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
KR20200087283A (ko) 2015-09-25 2020-07-20 제넨테크, 인크. 항-tigit 항체 및 이의 이용 방법
DK3347379T5 (da) 2016-08-17 2020-06-15 Compugen Ltd Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf
JOP20190133A1 (ar) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
US10537637B2 (en) * 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
EP3618863B1 (en) * 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antibodies and methods of use thereof
AR112603A1 (es) * 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
EP3484925B1 (en) 2017-07-27 2020-05-27 iTeos Therapeutics SA Anti-tigit antibodies
CA3082280A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
BR112020026862A2 (pt) * 2018-06-29 2021-04-20 Gensun Biopharma, Inc. antagonistas antitumorais de reguladores de pontos de verificação imunológica

Also Published As

Publication number Publication date
JP2022533457A (ja) 2022-07-22
JOP20210314A1 (ar) 2023-01-30
US20220227860A1 (en) 2022-07-21
CR20210573A (es) 2021-12-15
AR118980A1 (es) 2021-11-17
WO2020242919A1 (en) 2020-12-03
MX2021014472A (es) 2022-01-06
CL2021003039A1 (es) 2022-08-05
JP7241207B2 (ja) 2023-03-16
TW202110884A (zh) 2021-03-16
EA202192796A1 (ru) 2022-03-03
PE20220505A1 (es) 2022-04-07
DOP2021000241A (es) 2021-12-30
TWI760751B (zh) 2022-04-11
CN113939536A (zh) 2022-01-14
EP3976652A1 (en) 2022-04-06
AU2020283817A1 (en) 2021-11-25
BR112021021795A2 (pt) 2022-01-04
KR20220004120A (ko) 2022-01-11
MA56029A (fr) 2022-04-06
SG11202112725XA (en) 2021-12-30
IL287765A (en) 2022-01-01
JP2023071889A (ja) 2023-05-23
CA3139025A1 (en) 2020-12-03
CO2021015610A2 (es) 2021-11-30

Similar Documents

Publication Publication Date Title
ECSP21085693A (es) Moléculas de unión a tigit y pd-1/tigit
ECSP19013181A (es) Anticuerpos de anti-tim-3
CL2019001459A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1.
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
CO2018002009A2 (es) Anticuerpos que se unen al ligando 1 de muerte celular programada 1 humana (pd-l1)
ECSP20007663A (es) Anticuerpos anti-cd137
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
MX2020006668A (es) Anticuerpos para lilrb2.
MX2018001671A (es) Anticuerpos pd-1.
PH12020500075A1 (en) Checkpoint inhibitor bispecific antibodies